生物制剂对克罗恩病近端回肠病变疗效不足:一项前瞻性多中心研究
这项开放标签多中心前瞻性研究纳入253例活动性回肠克罗恩病患者,在第0周和第26周用球囊辅助小肠镜评估生物制剂对近端回肠病变的疗效。结果显示近端回肠内镜下缓解率(50.9%)低于结肠(63.4%)和末端回肠(56.7%),近端回肠残留溃疡与更差预后相关。
要点
- 近端回肠内镜下缓解率50.9%,低于结肠63.4%和末端回肠56.7%。
- 末端回肠溃疡完全愈合者中28.6%(22/77)近端回肠仍有残留溃疡。
- 近端回肠残留溃疡与住院(P=0.0126)和手术(P=0.0014)预后更差相关。
核心结论
- 相当比例克罗恩病患者存在近端回肠溃疡,且与更差预后相关。
- 无论使用何种生物制剂,近端回肠病变均难以愈合。
研究设计与样本
- 开放标签多中心前瞻性研究,在日本三级转诊中心开展。
- 纳入253例接受生物制剂(英夫利西单抗/阿达木单抗/乌司奴单抗/维得利珠单抗)治疗的活动性回肠克罗恩病患者。
- 第0周和第26周行球囊辅助小肠镜,内镜所见集中评估。
主要发现
- 基线时74例(29.2%)存在近端回肠溃疡而无末端回肠溃疡。
- 第26周第二次小肠镜显示91例(36.0%)达到内镜下缓解(最大改良Simple内镜克罗恩病评分<4)。
- 末端回肠溃疡完全愈合的患者中,28.6%(22/77)近端回肠仍有残留溃疡。
- 近端回肠内镜下缓解率为50.9%,结肠为63.4%,末端回肠为56.7%,所有治疗药物均呈现一致趋势。
- 中位随访134周后,近端回肠残留溃疡与更差预后相关(住院P=0.0126,手术P=0.0014)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Although biologic therapy has revolutionized the treatment of Crohn's disease (CD), surgery remains unavoidable in cases involving ileal complications. We aimed to evaluate the efficacy of biologics on proximal ileal lesions using balloon-assisted enteroscopy (BAE). METHODS: This open-label multicenter prospective study was conducted at tertiary referral centers in Japan. We enrolled 253 patients with active ileal CD who were treated with biologics (infliximab/adalimumab/ustekinumab/vedolizumab). BAE was performed at week 0 and week 26, and endoscopic findings were centrally assessed. We evaluated the rate of endoscopic remission (defined as having a maximum modified Simple Endoscopic Score for Crohn's disease <4) at week 26 and patient prognosis (CD-related hospitalization and surgery). RESULTS: At baseline, 74 patients (29.2%) had proximal ileal ulcerations without terminal ileal ulcerations. The second BAE showed that endoscopic remission was achieved in 91 patients (36.0%). Of the patients with complete ulcer healing of the terminal ileum, 28.6% (22/77) had residual ulcers in the proximal ileum. The rate of endoscopic remission in the proximal ileum (50.9%) was relatively lower compared with the colon (63.4%) and terminal ileum (56.7%), a trend consistently observed across all treatment agents. After a median follow-up of 134 weeks, residual ulcerations in the proximal ileum were associated with a poorer prognosis (P = .0126 for hospitalization and P = .0014 for surgery). CONCLUSIONS: A substantial proportion of patients with CD exhibited ulcerations in the proximal ileum, which correlated with a poorer prognosis. These lesions proved challenging to heal, regardless of the type of biologic used.
引用
- Takenaka K, Hisamatsu T, Kobayashi T, et al. Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn's Disease: A Prospective Multicenter Study. Clin Gastroenterol Hepatol. 2024. PMID: 39694212. doi:10.1016/j.cgh.2024.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。